Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

• Main Authors: Hari Krishna Ananthula (Author), Scott Parker (Author), Erin Touchette (Author), R. Mark Buller (Author), Gopi Patel (Author), Daniel Kalman (Author), Johanna S. Salzer (Author), Nadia Gallardo-Romero (Author), Victoria Olson (Author), Inger K. Damon (Author), Tessa Moir-Savitz (Author), Larry Sallans (Author), Milton H. Werner (Author), Catherine M. Sherwin (Author), Pankaj B. Desai (Author)
• Format: Book
• Published: BMC, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for "repurposing" as an...